<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="pmc">brjcancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">9275035</article-id><article-id pub-id-type="pmc">2227983</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Less efficacy with alternating regimen as adjuvant chemotherapy in stage II node-positive breast cancer: results at 8 years (Pronacam 85).</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chacon</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Romero Acu&#x000c3;&#x000b1;a</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Blajman</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Galvez</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bruno</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Romero</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Chiessa</surname><given-names>G.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bader</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Schwan</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Albera</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Santarelli</surname><given-names>M. T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sousa Mart&#x000c3;&#x000ad;nez</surname><given-names>F.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Nadal</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Viniegra</surname><given-names>M.</given-names></name></contrib></contrib-group><pub-date pub-type="ppub"><year>1997</year></pub-date><volume>76</volume><issue>4</issue><fpage>545</fpage><lpage>550</lpage><abstract><p>A randomized trial to compare adjuvant treatment with an alternating regimen with conventional chemotherapy was performed. A total of 589 node-positive patients were included and stratified according to number of positive nodes (N1-3 and N &#x0003e; 4) and menopausal status. Premenopausal N1-3 patients were randomized to cyclophosphamide, methotrexate and fluorouracil (CMF) or CMF/4'-epirubicin, cyclophosphamide (EC), post-menopausal N1-3 patients to fluorouracil, 4 epirubicin, cyclophosphamide (FEC) or CMF/EC and pre- and post-menopausal patients with N &#x0003e; or = 4 to fluorouracil, 4' epirubicin, cyclophosphamide, methotrexate, prednisone (FECMP) or CMF/EC. In premenopausal patients, CMF was superior to CMF/EC in terms of disease-free survival (DFS) (65% vs 45%, P = 0.0149) and survival (72.3% vs 50.2%, P = 0.0220) whereas, for N &#x0003e; or = 4 patients, differences between FECMP and CMF/EC did not achieve statistical significance (DFS 35% vs 26.2%; survival 50% vs 38.1%, P = NS). For post-menopausal patients, FEC was superior to CMF/EC in DFS (58.6% vs 36.8%, P = 0.0215) and survival (66.2% vs 46%, P = 0.0155). In post-menopausal patients with N &#x0003e; 4, differences favouring CMF/EC were significant in DFS (40.4% vs 22%, P = 0.0371) but not in survival (47.4% vs 32.2%, P = 0.1185). Alternating regimens did not offer better results in premenopausal and post-menopausal N1-3 patients. Results regarding post-menopausal N &#x0003e; 4 women require further confirmation.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00168-0129.tif" xlink:title="scanned-page" xlink:role="545" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00168-0130.tif" xlink:title="scanned-page" xlink:role="546" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00168-0131.tif" xlink:title="scanned-page" xlink:role="547" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00168-0132.tif" xlink:title="scanned-page" xlink:role="548" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00168-0133.tif" xlink:title="scanned-page" xlink:role="549" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00168-0134.tif" xlink:title="scanned-page" xlink:role="550" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

